The t(9; 14)(p13;q32) translocation is associated with approximately 50% of lymphoplasmacytoid lymphoma (LPL), a subtype of B-cell non-Hodgkin's lymphoma (NHL). We cloned the chromosomal breakpoint of der (14) from an LPL case (1052) and showed that it involved a junction between 9p13 and the switch y region of the Ig heavy chain locus (IgH) on 14q32. Using a VAC contig spanning 1.5 megabase (Mb), we determined that the 9p13 breakpoint in one case (1052) mapped within a 270-kb restriction fragment containing two previously reported 9p breakpoints associated with a a-heavy chain disease case (MAL) and Ki-1 positive diffuse large cell lymphoma (DLCL) cell line (KIS-1). The same fragment also contained the PAX-5 gene which encodes a B-cell specific transcription factor involved in the control of B-cell proliferation and differentiation. The breakpoints of KIS-1 and 1052 were mapped within the 5' noncoding region of PAX-5, while the 9p13 breakpoint of MAL mapped 230 t o ONRANDOM CHROMOSOMAL translocations are N typically associated with lymphoid neoplasms where they involve a number of protooncogene loci.' In B-cell nonHodgkin's lymphoma (NHL), translocations deregulate these proto-oncogenes by juxtaposition with regulatory elements of genes expressed normally in the cells, most frequently immunoglobulin genes (Zg )? Different chromosomal translocations are associated with specific subtypes of lymphoma, and substantial experimental evidence, including studies in transgenic mice, indicates that most these oncogenes contribute specifically to lymphomagenesis. For instance, t(8; 14)(q24;q32), t(8; 22)(q24;ql l), and t(2;8)(p12;q24) lead to the deregulated expression of the c-MYC proto-oncogene by juxtaposition to one of the Ig loci in 100% of Burkitt's lymph~ma.~ Similarly, rearrangement and deregulation of the antiapoptotic gene, BCL-2, caused by t(14;18) (q32;q21) has been shown in 70% to 90% of follicular lymph0mas.4.~ In approximately 50% of mantle cell lympho- In all three cases, the translocation caused the juxtaposition of the PAX-5 gene t o the IgH locus in the opposite direction of transcription. When compared with six other DLCL cell lines lacking t(9; 14)(p13;q32), the KIS-1 cell line showed an 11-fold overexpression of PAX-5 mRNA and a significantly reduced expression of the p53 gene, which is normally regulated by PAX-5. Moreover, metaphase and interphase fluorescence in situ hybridization (FISH) analysis using a VAC clone spanning 1 Mb including the PAX-5 as a probe identified chromosomal translocations in 5 of 7 cases carrying 9p13 translocations. These findings suggest that the PAX-5 gene is the target of the t(9;14) in LPL whereby its expression may be deregulated by juxtaposition t o IgH regulatory elements, thus contributing t o lymphomagenesis.
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mas, the t(l1; 14)(q13;q32) results in the overexpression of BCL-I (Cyclin DI/PRADI), which regulates cell-cycle progression, by juxtaposition with the IgH gene."' The BCL-6 gene, encoding a POZ-zinc-finger transcription factor, is altered by rearrangements or mutations involving its 5' noncoding region in the majority of diffuse large cell lymphomas (DLCL) and less frequently in follicular lymphoma^."^ The t(9; 14)(p13;q32) is associated with 50% of lymphoplasmacytoid lymphoma (LPL)/immunocytoma (Revised European-American Classification of Lymphoid Neoplasms [REAL] ; small lymphocytic lymphoma with plasmacytoid differentiation according to the Working Formulationlo."). This rare type of lymphoma is characterized by the infiltration of B cells displaying a lymphoplasmacytoid phenotype, the presence of cytoplasmic Ig and serum paraproteins, and an indolent clinical course followed by transformation into large cell lymphoma." LPL are associated with translocations involving chromosome 9p13, which are ''promiscuous" in that various chromosome loci including 14q32, lq25, 3q27, 7ql1, 12q13, 12q21, 19~13, and 9q13 can act as reciprocal translocation partners in different cases." Two distinct breakpoint regions linking 9pl1 and 9p13 sequencies to the Ig heavy-chain locus (ZgH) on 14q32 have already been cloned from a case (MAL) of a-heavy chain disease'' and a Ki-1 positive DLCL cell line (KIS-l),I4 respectively. However, the gene on 9p13 involved in these translocations has not been identified.
In further pursuit of the target gene involved in 9p13 translocation, we analyzed the breakpoint of a typical LPL case and compared its genomic location with two previously identified cases. This approach led us to identify that the translocation breakpoints at 9p13 of all three cases are located within a 270-kb region containing the PAX-S(paired homeobox-5) gene.l5.l6 A YAC probe spanning this region could also identify chromosomal rearrangements in five out of seven (71%) cases with 9p13 translocations by fluorescence in situ hybridization (FISH) analysis. This structural analysis together with the finding of overexpression of the PAX-5 mRNA in the IUS-1 cell line suggest that the t(9; 14)(p13; q32) translocation deregulates the expression of the PAX-5 gene by juxtaposition to the Ig regulatory elements.
MATERIALS AND METHODS
Tumor biopsies and cell lines. The biopsy (case 1052, 79-yearold woman) sample analyzed was derived from a retroperitoneal lymph node diagnosed as LPL. Cytogenetic analysis showed that 16 of 16 metaphases had 46, XX, t(9; 14)(p13;q32). Detailed clinical characteristics were previously reported." The KIS-1 cell line derived from a Ki-l positive DLCL with t(9; 14)(p13;q32) was previously des~ribed.'~." The RC-K8 and LY1, 2, 3, 17, 18 cell lines were kindly provided by Dr I. Kubonishi (Kouchi Medical College, Kouchi, Japan) and Dr H.A. Messner (Ontario Cancer Institute, Toronto, Canada), Southem blot analysis was performed as described previously.zo A 1.3-kb EcoRI-EcoRI Cp probe and a 6.6-kb BamHI-Hind111 JH probe were kindly provided by S.J. Korsmeyer (Washington University, St Louis, MO).
Cloning of chromosomal breakpoints. High-molecular-weight DNA from case 1052 was partially digested with Sau3AI and sizefractionated by using a low-melting point agarose gel. DNA fragments ranging from 15 to 23 kb were gel-purified, ligated into the A dash I1 vector (Stratagene, La Jolla, CA) and in vitro packaged. Recombinant clones, 5 X lo5 were screened by plaque hybridization using the C p and JH probes. A human placental DNA library purchased from Stratagene was used for the isolation of 9p13 gennline sequences.
Polymerase chain reaction (PCR) primers, probe preparation, and YAC library screening. STS primers (sense 5'-GGAAAT-GCCCTCCTACTG-3'; antisense 5'-GACAAGCCAGTAGCT-AAG-3') were designed from the 9p13 sequence in the vicinity of MAL case's breakp~int.'~ The amplified 153-bp PCR product was also used as a probe (MAL). PCR primers (sense 5'-CACAGTGGC-AACCTTCAG-3'; antisense 5'-TGAGAGACCTGGCTCTAG-3') derived from the 9p13 sequence surrounding the 1052 breakpoint were prepared based on the sequence of the 1.5-kb Hind111 fragment, which was also used as a probe (1052-1.5H) (Fig 1B) . These PCR primers were used to screen a human CEPH YAC DNA pools (Research Genetics, Huntsville, AL). Extraction of YAC DNA was performed according to standard techniques." PAX-5 gene probes were prepared by reverse transcription (RT)-PCR using primer sets to amplify nucleotides 46 to 675 (PAX- and FISH were performed as previously described." The signals from the YAC were scored in metaphases andor interphases from archival fixed suspensions of tumor chromosome preparations. In metaphase preparations, the der (9) and the der (14) chromosomes were identified and analyzed for the presence of hybridizing signal. Presence of the signal on both chromosomes at the breakpoint confirmed rearrangement. In interphase preparation, presence of three signals in a significant proportion of cells was considered as evidence of the chromosomal translocations involving signals represented by the YAC. Isolation of YAC end clones and construction of the YAC contig. A vectorette-PCR method was used to isolate YAC end probes.
Southern blot analysis.
Briefly, 500 ng of each YAC DNA were digested with Rsa I, Dde I, and Bfn I and ligated with specific vectorette linkers as described by Riley et al?3 First-round PCR was performed using 224 primer (5'-CGAATCGTAACCGTTCGTACGAGAATCGCT-3') and YAC vector-specific HYACD primer (5'-GGTGATGTCGGCGATATA-GGCGCCAGCAAC-3') for the right arm and HYACC primer (5'-GCTACTTGGAGCCACTATCGACTACGCGAT-3') for the left arm. A seminested second-round PCR was performed using 224 primer and RA-2 primer (5'-TCGAACGCCCGATCTCAAGAT-TAC-3') for the right arm and LS-2 primer (5'-TCTCGGTAGCCA-AGTTGGWAAGG-3') for the left arm to isolate each YAC end.
Localization on chromosome 9 of gel-purified each YAC end probe was confirmed by hybridization to somatic cell hybrid DNAs containing human chromosome 9 (NIGMS Human Genetic Mutant Cell Repository, Coriell Institute, Camden, NJ). Overlapping between YAC clones were evaluated by Southern hybridization.
Pulsed-field gel electrophoresis (PFGE) analysis. Yeast cells were embedded in agarose plugs by a standard method,*' and analyzed by PFGE after restriction enzyme digestion using the CHEF DR I1 (Bio-Rad, Richmond, CA) as described p r e v i o u~l y .~~ The insert size of each YAC clone was determined by hybridization with total human DNAs to a nondigested plug. Mapping of the YAC insert was achieved by partial digestion of the YAC DNA followed by hybridization with both YAC end (right and left arms) probes. Double digestions were also used for detailed analyses.
Northern blot analysis and cDNA library screening. Total RNA was prepared by the guanidium thiocyanate method and poly(A) RNA was selected using Oligotex coated with poly(T) (Qiagen, Chatsworth, CA). Northern blot analyses were performed as described previously." l X lo6 plaques from a cDNA library constructed from the BJAB cell line were screened with the PAX-5 5' cDNA probe.
DNA sequencing was performed by the dideoxy chain termination method using an automated sequencing system, AB1 473A (Applied Biosystems, Foster City, CA).
DNA sequencing.

RESULTS
Molecular cloning of the t(9; 14) breakpoint region in an LPL case. Southern blot analysis of BamHI-digested DNA from case 1052 using the Cp probe showed two rearranged bands (Fig 1A) . One of these bands (8.0 kb) did not comigrate with the JH band in the BamHI digest, suggesting the existence of a chromosomal breakpoint between the JH and Cp loci of the ZgH gene. To clone this fragment, a genomic library was constructed and screened with both Cp and JH probes. As a result, we isolated a clone (A4) containing the IgH Sp region juxtaposed to an unknown fragment (Fig  l e ) . FISH analysis showed that clone A4 hybridized to both 14q32 and 9p13 chromosomal loci on normal metaphase spreads (data not shown), indicating that it represented the breakpoint region of the der (14) chromosome. Localization to chromosome 9 was also confirmed by hybridization to a somatic cell hybrid panel with the 1052-1.5H probe (data not shown).
Three NHL-associated 4 1 3 breakpoints map within a 270-kbgenomicregioncontainingthePAX-5 locus. Restriction mapping of clone A4 showed that the sequences involved in the breakpoints of case 1052 and those previously reported in MAL and IUS-1 were independent from each other. To investigate the genomic distance between these three breakpoints, we isolated YAC clones spanning this region. For this purpose, we designed STS primers in the Clone A4 (der.14)
-
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vicinity of each breakpoint, and screened a CEPH YAC library. Overlapping YAC clones spanning 1.5 Mb were isolated and mapped to the 9p13 locus by FISH analysis (Fig 2, FISH data not shown) . A representative YAC contig (Fig 2) was constructed based on the overlapping hybridization pattem given by YAC end probes. Using mapping by PFGE, we found that the three breakpoints were located within 270 kb which also contained the PAX-5 gene, recently assigned to the. 9p13 locus.2s In addition, two of the breakpoints (case 1052 and KIS-1) mapped within the same 150-kb Nru YNot I fragment (Fig 3) , while the breakpoint of case MAL mapped 230 to 270 kb upstream to the PAX-5 locus. Relationship between 9pl3 breakpoints and the PAX-5 gene. To precisely determine the genomic distance between the breakpoints and PAX-5 gene sequences, we iso- (Fig 4A) . Nucleotide sequencing showed that this clone contained a putative alternative in-frame translation initiation site (ATG), partly corresponding to Kozak's consensus sequence" (Fig 4B) . The N-terminal sequences of the protein putatively encoded by this cDNA species differ from those previously reported for PAX-5, although the main functional domains of the protein remain conserved. Consistent with these two cDNA species, Northern analysis showed two alternatively spliced transcripts of I O kb and 10.5 kb, using a PAX-5 probe derived from the 3' end (Fig 4C) . On the other hand, the IO-kb and 10.5-kb transcripts were specifically detected by the pKIS and 1.7B genomic probes, respectively, suggesting that the 5' region of PAX-5 contains two altematively used first exons ( l a and l b in Fig 4D) . Most B-cell lines (eg, RC-K8 and KIS-I) express both the IO-kb and the 10.5-kb transcripts, which use the first (ATGI) and second translation initiation site (ATG2). respectively. Only the 10-kb transcript is detectable in the RAMOS cell line by Northem analysis, although the 10.5-kb mRNA species was also identified by RT-PCR analysis (data not shown).
The breakpints of KIS-I and case 1052 mapped 2.5 kb upstream to the ATGI site and just 5' to the ATG2 site within exon I b (Fig 4B and D) . In both cases, the PAX-5 gene was juxtaposed to the IgH locus in the opposite direction to transcription as a result of the ((9; 14) translocation. In case 1052, ((9; 14) removed the enhancer p (Ep) element and the ATGl site of PAX-5, while in the case of the IUS-I cell line, the Ep sequences and both PAX-5 exon 1 s remain on der (14). The PAX-5 gene is overexpressed in a cell line carrying t(9; 14). To determine whether the juxtaposition to IgH had any effect on PAX-5 gene expression, we compared PAX-5 RNA levels in KIS-I and other DLCL cell lines sharing the same histological subtype, but lacking t(9; 14)(p13;q32) ( Fig  5) . Densitometric analysis of the hybridization bands showed an 1 I-fold overexpression in the KIS-I cell line when compared with the mean value of the other six cell lines.
The p53 gene, which is negatively regulated by PAX-5, is downregulated in an NHL cell line containing t(9; 14) and overexpressing PAX-5. The expression of the p53 gene is physiologically modulated by PAX-5.*' Because the KIS-1 cell line overexpresses PAX-5, we examined whether this was associated with p53 downregulation by analyzing p53 RNA levels in KIS-I cells versus 6 control NHL lines. The results showed that p53 RNA expression is significantly repressed in KIS-I cells (Fig 5) .
Frequent detection of 9p13 breakpoint in LPL by FISH analysis. To investigate the frequency of the PAX-5 gene involvement in B-cell NHL, we analyzed 20 LPL cases, including 2 cases with t(9; 14) and a panel of 50 lymphoma cases representative of the main NHL subtypes by Southern blot analyses using the MAL, pKIS, and 1.7B probes. However, we did not detect any rearrangement (data not shown), suggesting that none of the probes used was representative of a rearrangement cluster. We then decided to use the CEPH788C3 YAC DNA as a probe for metaphase and/or interphase FISH analysis to examine a larger genomic region spanning the PAX-5 gene. Seven B-cell NHL cases, including 3 LPL and 2 DLCL cases with t(9; 14)(p13;q32) and 2 DLCL cases with other translocations involving 9p13 ( Table  1) were selected for this analysis. The results show that 3 LPL and a DLCL case carrying . -P A X 4 S P A X 4 3' t(9;14), together with 1 DLCL case with a t(3;9)(q27;p13) show rearrangements of 9p13 within the genomic region represented by the YAC clone (Table I , Fig 6) .
DISCUSSION
The t(9; 14)(pl3;q32) translocation is a recurrent chromosomal abnormality associated with a significant fraction of LPL cases and less frequently with other NHL subtypes.'" Our results identify a chromosomal subregion at 9p13 which is involved in this translocation in most cases of LPL and provides evidence in a few cases that the chromosomal breakpoints directly involve the PAX-5 gene. These results have implications for the consequences of t(9; 14)(p13;q32) on PAX-5 expression, for the role of PAX-5 in lymphomagenesis, and for the possible diagnostic use of 9p13 breakpoints in NHL diagnosis.
Consequences of t(9; 14)(p13;q32) on PAX-5 gene expression. Our results show that 9p13 chromosomal breakpoints are located within a 270-kb genomic region which contains the PAX-5 gene in three cases. In addition, the fact that the 9p13 breakpoints were detected by the 1-Mb YAC containing the PAX-5 gene in 6 of 8 NHL cases by FISH analysis indicates that the breakpoints may be in relative proximity to the PAX-5 gene in most LPL and DLCL cases. In analogy to the chromosomal translocations involving the IgH locus and the BCL-I, BCL-2, or c-MYC loci in other types of NHL,?'.'" it is conceivable that at these distances IgH gene regulatory elements such as IgH transcriptional enhancers and locus control regions-" may deregulate PAX-5 expression. This model is directly supported by the findings in case KIS-I and case 1052, where the IgH locus 
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' 10.0 hb mRNl . : -. : ... is directly juxtaposed to the PAX-5 gene in the opposite direction of transcription, and by the striking overexpression of the PAX-5 mRNA in the KIS-I cell line. In addition, the observation that the 9 p l 3 locus seems to be disrupted also in reciprocal translocations involving partner chromosomes other than 14q32 (see case 1615 in Table I ) suggests that multiple chromosomal regions may contribute to PAX-5 deregulation perhaps by juxtaposing different regulatory elements, a mechanism analogous to that observed for chromosomal translocations involving the BCL-6 gene in DLCL.*
The PAX gene family include a number of transcription factors which share homologous DNA binding and dimerization domains, desig-
Role of PAX-5 in l~mnpliorna~eriesis.
nated as paired domains, and are characterized by a highly conserved a-helical structure at the N Through transcriptional regulation of downstream genes, PAX genes control embryonal development and organogenesis. In addition, various PAX genes have been implicated in oncogenes k J 4 The PAX-3 and PAX-7 genes have been shown to fuse to fork head domain gene (FKHR) by t(2: 13)(q35:q14) and t( 1 : 13)(p36;q 14) translocations in alveolar rhabdomyosarThe PAX-2 and PAX-5 genes have been found coma.3s.36 highly expressed in Wilms' tumor," and in brain tumors such as medulloblastoma and glioblastoma,3x respectively. although the mechanism responsible for their altered expression has not been identified. 
P53
The PAX-5 gene was cloned as a human homolog of the sea urchin TSAP (tissue-specific activator protein), and turned out to be the gene encoding 50-kD BSAP (B-cell lineage specific activator protein)." PAX-5 is expressed in fetal brain and liver during the embryonic period and, after birth, is exclusively expressed in B lymphocytes and testis. Several observations suggest that PAX-5 plays a significant role in the control of B-cell proliferation and differentiation. Its loss of function results in a maturation arrest at the pro-B cell stage39 and its overexpression results in proliferation of splenic B cells.40 On the other hand, treatment with antisense oligonucleotides strikingly reduces lipopolysaccharide-induced proliferation of splenic B cells and spontaneous proliferation of B-lymphoma cell lines?" Furthermore, PAX-5 gene expression is upregulated by the product of the E2A proto-oncogene,'" whereas PAX-5 itself downregulates the expression of ~53." Taken together, these observations suggest that PAX-5 is crucial in the control of proliferation of mature B cells and that its deregulated expression may contribute to abnormal proliferation and thus to lymphomagenesis.
In this study we have also identified alternative transcripts and translation initiation sites that had not been previously reported for the PAX-5 gene. Interestingly, the amino acid sequence (MEIHCKHDPFASMH) encoded by the novel exon Ib identified in this study is 92% homologous to that (MDMHCKADPFSAMH) encoded by exon 1 of the PAX-2 gene," suggesting that this domain may have functional significance. Alternatively spliced mRNAs encoding different open reading frames are found in the same (class 111) PAX family genes including P A X 2 and PAX-8,42"3 and in the PAX-8 gene such alternative forms are developmentally regulated and generate isoforms with different transactivation properties. These observations suggest that the two PAX-5 mRNAs (10.0 kb and 10.5 kb) which are expressed in most B-cell lines may encode functionally distinct proteins, whose role in normal B-cell development and possibly lymphomagenesis requires further investigation.
Alterations of the PAX-5 gene represent the first molecular lesion found in association with LPL. However, the low frequency of this rearrangement detected by conventional Southern analysis suggests the possibility that the breakpoints at 9p13 may be dispersed within a several-hundred kilobase range or the existence of multiple breakpoint cluster regions. Metaphase andor interphase FISH analysis of NHL samples using the 1-Mb CEPH788C3 YAC spanning the PAX-5 gene as a probe may complement Diagnostic implications.
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From or substitute conventional cytogenetic analysis for detecting these chromosomal abnormalities. In addition, this approach may facilitate the detection of cytogenetically undetectable 9pl3 rearrangements. Finally, 9p 13 rearrangements, which are common in LPL, but occasionally present in DLCL, may represent useful clonal markers to determine whether some LPL cases can progress into DLCL.
